Europium chloride, anhydrous 99.9% → Thyroxine

HRID 257615

Reaktionsgleichung

Reaktionsgleichung von HRID 257615
[Cl-].[Eu+3].[Cl-].[Cl-].[Na+].[NH2:6][C@H:7]([C:27]([O-:29])=[O:28])[CH2:8][C:9]1[CH:16]=[C:14]([I:15])[C:13]([O:17][C:18]2[CH:25]=[C:23]([I:24])[C:22]([OH:26])=[C:20]([I:21])[CH:19]=2)=[C:11]([I:12])[CH:10]=1>CN(C)C=O.C(O)C>[NH2:6][C@H:7]([C:27]([OH:29])=[O:28])[CH2:8][C:9]1[CH:10]=[C:11]([I:12])[C:13]([O:17][C:18]2[CH:19]=[C:20]([I:21])[C:22]([OH:26])=[C:23]([I:24])[CH:25]=2)=[C:14]([I:15])[CH:16]=1

Komponenten

5

Edukt 2

HCID 9859933Europium chloride, anhydrous 99.9%HCID 23666112Levothyroxine Sodium2×

Produkt 1

HCID 5819Thyroxine

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 702EthanolLösungsmittel2×HCID 6228DimethylformamideLösungsmittel

Versuchsvorschrift

Fluorescent compound (v) synthesized in Example 4 was dissolved in dimethylformamide at a concentration of 5.0×10-5M, and thyroxine sodium salt was dissolved in ethanol at a concentration of 5.0×10-5M. The fluorescent compound (v) solution (100 μl) and the thyroxine sodium salt solution (100 μl) of ethanol were mixed and incubated for 30 minutes at room temperature with stirring. The resulting solution was subjected to a HPLC purification (column: AP-313, YMC Co., solvent: methanol: water=3:7(v:v) including 0.02% acetic acid) and the fluorescent compound (v)-labelled thyroxine was purified. The fluorescent compound (v)-labelled thyroxine was identified by measuring the thyroxine activity using an enzyme immunoassay (Boehringer Mannheim GmbH), and by measuring fluorescence intensity of the solution prepared by mixing equal volume of europium chloride (1×10-5M) and the fraction.

Aufarbeitung

  1. customThe resulting solution was subjected to a HPLC purification (column: AP-313, YMC Co., solvent: methanol: water=3:7(v:v)
  2. customwas purified
  3. customprepared

Quellen und Nachweise

ORD-Eintrag
ord-47de7a514e3547679a0e2c8e966c64ef
Quelldatensatz
uspto-grants-1993_11
Patentnummer
US05262526

Verknüpfte Notizen

Wird geladen…